Different Abbreviated MRI for Hepatocellular Carcinoma Diagnosis
NCT ID: NCT06663904
Last Updated: 2024-10-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
938 participants
OBSERVATIONAL
2021-01-01
2023-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High Risk
NCT07010588
Study on the Quantitative Assessment of the Risk of Hepatocellular Carcinoma in Patients With Chronic Liver Disease Using Multi-parameter Magnetic Resonance Imaging
NCT06060769
Hepatic Arteriography in Liver Cancer Diagnosis and Staging Applications
NCT02936856
Non-contrast Abbreviated MRI for Secondary Surveillance of HCC
NCT05690451
Role of Abbreviated MRI in Follow-up of Hepatocellular Carcinoma .
NCT06168357
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HCC group
No previous treatments were performed before MRI examination of patients.
No interventions assigned to this group
Non-HCC group
No previous treatments were performed before MRI examination of patients.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* no history of any other underlying malignancy besides HCC.
Exclusion Criteria
* For non-HCC group: 1) lost follow-up, 2) insufficient follow-up period, or 3) suboptimal imaging quality.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
First Affiliated Hospital, Sun Yat-Sen University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yanjin Qin
clinical doctor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
China, Guangdong
Guangzhou, Guangdong, China
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Qin Y, Zhang J, Xu D, Zhou X, Ling Z, Li L, Zhao Q, Dong Z, Wang J, Cai HS, Li H, Zhang LG, Feng ST. Diagnosis of Hepatocellular Carcinoma Using Gadoxetic Acid-Enhanced MRI Based on LI-RADS Version 2018 and LI-RADS Modifications. Liver Int. 2025 Nov;45(11):e70366. doi: 10.1111/liv.70366.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
82271958
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
2024A1515012149, 2023A15150110
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
SYSUFAH2021124
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.